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Edited by Ga´spa´r Je´kelyAbstract It is now well established that Toll-like receptors
(TLRs) act as primary sensors of microbial compounds. Details
of the molecular mechanisms governing TLR responses are
emerging steadily and our understanding of the signaling path-
ways activated these receptors has improved greatly over the last
few years. Diﬀerences in adaptor usage, cellular localisation and
signaling cascades have been elucidated. In this review we will
summarize the current understanding of TLR signaling and its
regulation.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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It is now well established that Toll-like receptors (TLRs)
represent a primary line of defence against invading pathogens
in mammals, plants and insects. Recognition of microbial
components by these receptors triggers the initial innate im-
mune response that ultimately leads to inﬂammatory gene
expression and clearance of the infectious agent. Among the
structures recognized by TLRs are lipids, carbohydrates, nu-
cleic acids and various proteins, collectively referred to as
pathogen associated molecular patterns or PAMPs [1]. The
receptors themselves have evolved with the capacity to distin-
guish diﬀerent PAMPs, although this remains one of the more
complex features of TLR activation (in many cases direct li-
gand binding has not yet been demonstrated). Eleven TLRs
have been identiﬁed in humans while 13 can be found in
searches of the mouse genome. TLRs 1-9 are conserved be-
tween both species. All share a common cytosolic TIR (Toll/
interleukin-1 receptor) domain (also found in members of
the interleukin-1 (IL-1) receptor family) and an extracellular
leucine rich repreat region that mediates recognition of micro-
bial by-products.
TLR4 was the ﬁrst human TLR to be identiﬁed and was for
some time considered the prototypic TLR. Diﬀerences are now
beginning to emerge particularly in the signaling pathways
emanating from the various receptors. Some of these diﬀer-
ences arise due to the diﬀerential utilization of a group of cyto-
solic proteins referred to as adaptor molecules. They are so
called because they function to couple TLRs to downsteam*Corresponding author. Fax: +353 6772400.
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These molecules also possess the signature TIR domain which
serves as a point of contact between the receptors and the adapt-
ors themselves. Another notable diﬀerence results from the dif-
ferential activation of kinase cascades that serve as the link
between membrane proximal events and gene expression in
the nucleus. Finally, the expression pattern of TLRs diﬀers both
inter-and intra-cellularly. Positive staining of the cell surface
with antibodies to speciﬁc TLRs reveals that TLR1, TLR2,
TLR4, TLR5 and TLR6 are all localized to the plasma
membrane whereas TLR3, TLR7, TLR8 and TLR9 are prefer-
entially expressed in intracellular compartments such as endo-
somes (see Fig. 1) [1]. The nature of the ligand recognized by
individual TLRs seems to determine their expression pattern.
For example, TLR3, TLR7, TLR8 and TLR9 all recognize nu-
cleic acid structures whereas TLR1, TLR2, TLR4, TLR5 and
TLR6 generally recognize cell wall components. It should be
noted however that surface exposed TLRs are not completely
restricted in their expression pattern, for example, TLR2 can
localize to phagosomes following exposure to certain ligands [2].
In this review, we will summarize some of the signaling
events triggered following TLR occupation. We will also high-
light the diﬀerences that are now emerging between TLRs and
classify them based on their ability to signal from the cell mem-
brane or intracellular compartments.2. Plasma membrane associated TLRs
2.1. TLR4
The recognition of lipopolysaccharide (LPS) or endotoxin
by TLR4 remains one of the most extensively studied aspects
of TLR signaling. The most compelling evidence that LPS
was acting through TLR4 came from studies on a strain of
mice called the C3H/HeJ mice. These mice have a point muta-
tion in the gene encoding TLR4 that renders them hypore-
sponsive to LPS challenge [3]. It later emerged that TLR4 is
also a receptor for endogenous ligands such as ﬁbrinogen, heat
shock proteins (HSP 60 and HSP 70), ﬁbronectins and hyalu-
ronic acid [4]. However, the doses at which these compounds
were found to activate TLR4 far exceeded those required for
the activation of TLR4 by LPS and it is also suspected that
these preparations may have been contaminated with traces
of LPS. It therefore remains to be seen if these compounds
are true TLR4 ligands. At the molecular level, great progress
has been made in understanding the signal transduction path-
ways activated following TLR4 stimulation. As will be dis-
cussed, many features are common to other TLR signaling
pathways.blished by Elsevier B.V. All rights reserved.
Fig. 1. Cellular localisation of TLRs. TLR1, TLR2, TLR4, TLR5 and TLR6 reside mainly in the plasma membrane whereas those TLRs recognizing
nucleic acid derivatives are localized to intracellular compartments such as endosomes.
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and recruits two sets of adaptor molecules. MyD88 and
MyD88 adaptor-like (Mal) (also known as TIRAP) function
together to activate the early phase of NF-jB activation which
results in the production of pro-inﬂammatory cytokines, den-
dritic cell maturation and the up-regulation of co-stimulatory
molecules [5–7]. TRIF [8] and TRAM [9,10] activate the late
phase of NF-jB activation and a second pathway leading to
the production of the type I interferon, IFN-b. The Mal/
MyD88 pathway was the ﬁrst to be characterized and in many
ways resembles that seen following exposure of cells to IL-1.
Unlike MyD88, Mal is not required for IL-1 signaling and
its role in TLR4 signaling appears to be structural one, acting
as a bridge to couple MyD88 to TLR4. MyD88 diﬀers from
Mal in that it also possesses an N-terminal death domain. This
domain serves to recruit members of the IL-1 receptor associ-
ated kinase (IRAK) family of which there are four. IRAK-1
and IRAK-4 possess intrinsic serine/threonine kinase activity
[11,12] whereas IRAK-2 and IRAK-M are catalytically inac-
tive due to the absence of key residues in their respective kinase
domains [13,14]. IRAK-4 is thought to function upstream of
IRAK-1 and has been shown to phosphorylate IRAK-1 in vi-
tro [15]. Upon activation, IRAK-1 engages with tumor necro-
sis factor (TNF)-receptor-associated factor 6 (TRAF6), a
member of the TRAF family of proteins [16]. TRAF6 func-
tions in both TNF-receptor and IL-1R/TLR signaling and reg-
ulates an array of physiological processes including
inﬂammatory responses and bone metabolism [17,18]. It has
recently been demonstrated that TRAF6 undergoes ubiquiti-
nation following cell stimulation and that TRAF6 itself is a
ubiquitin ligase [19]. This modiﬁcation does not prime TRAF6
for degradation but rather activates the protein and subse-
quent downstream kinase cascades. Once ubiquitinated,
TRAF6 activates IKK through a TAK1-TAB1-TAB2 kinase
complex [20]. Ea and co-workers [21] have also demonstratedthat TAB2 binds to Lys-63 linked polyubiquitin chains
through a conserved novel zinc ﬁnger domain which is essen-
tial for TAK1 activation. Once activated, TAK1 phosphory-
lates the activation loop of IKKb, thereby activating the
IKK complex and the pleiotropic transcription factor, NF-
jB. TAK1 also phosphorylates MKK6 and 7, which in turn
activate the p38 and JNK kinase pathways, respectively [20].
TLR4 utilizes the adaptors TRIF and TRAM independently
of Mal and MyD88 to initiate the late phase of NF-jB activa-
tion and also to induce the expression of IFN-b and other
IFN-inducible genes via the transcription factor IRF-3 [22].
TRAM, like Mal, acts as a bridge to couple TRIF to TLR4
and is absolutely required for TLR4 mediated responses.
TRAM/ mice are completely impaired in their responses
to LPS while Mal or MyD88 deﬁcient mice do respond albeit
with delayed kinetics [23–25]. TRIF is the largest of the adap-
tor molecules and structurally can be subdivided into three dis-
tinct regions. The N-terminus of TRIF contains binding sites
for TRAF6 and the non-canonical kinases IKKi and TBK1,
the TIR domain presumably tethers TRIF to its binding part-
ner TRAM and ﬁnally the C-terminus of TRIF contains a
RIP-1 binding site. Both TRAF6 and RIP-1 are thought to
mediate TRIF induced NF-jB activation whereas IKKi and
TBK1 are required for TRIF-induced IRF-3 activation. A
more detailed description of IRF-3 activation is presented be-
low in the context of TLR3 signaling which also requires the
adaptor molecule TRIF.
2.2. TLR1, TLR2, TLR5 and TLR6
TLR2 recognizes a vast array of microbial components
including lipoproteins from various pathogens, peptidoglycan
from gram positive bacteria, glycophosphatidylinositol (GPI)
anchors from malaria causing parasites, zymosan from fungi
and forms of LPS that are structurally distinct from those
recognized by TLR4 [1]. The ability of TLR2 to recognize such
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of TLR2 to heterodimerize with other TLRs, namely TLR1
and TLR6. The association of TLR2 with TLR1 permits the
recognition of triacyl lipopeptides whereas TLR2/TLR6 het-
erodimers recognize diacyl lipopeptides [26,27].
TLR2 is similar to TLR4 in that it utilizes the adaptors Mal
and MyD88 to transmit signals to NF-jB however there is no
evidence for a TRIF/TRAM pathway post ligand binding.
Biochemical studies with heat-killed Staphylococcus aureus
(HKSA) have demonstrated that phosphorylation of TLR2
on speciﬁc tyrosine residues facilitates the recruitment of
PI3K, an eﬀector of the small G-protein, Rac-1 [28]. The p85
subunit of PI3K binds to phospho-tyrosine residues via a
src-homology domain. Phosphorylation of TLR2 by an as
yet unidentiﬁed kinase induces the formation of an active
TLR2–Rac1–PI3K complex. The adaptors Mal and MyD88
are presumably recruited to the receptor at the same time
and initiate a signaling pathway leading to IjB degradation
and nuclear translocation of active p50/p65 NF-jB heterodi-
mers. Rac-1 participates in the transactivation of NF-jB
which occurs following the binding of NF-jB to its consensus
response elements within the nucleus [29]. PI3K has also been
implicated in the TLR4 signaling pathway, again acting as a
mediator of NF-jB transactivation [30]. In this case, PI3K
does not bind directly to TLR4 but rather interacts with
TLR4 through MyD88.
TLR5 recognizes ﬂagellin, a monomeric constituent of bac-
terial ﬂagella [31]. A stop codon polymorphism in the ligand-
binding domain of TLR5 is associated with susceptibility to
legionnaires disease [32] thus highlighting the importance of
TLR5 in microbial recognition particularly at the mucosal
surface.3. Intracellular TLRs
Among the nucleic acid recognizing TLRs, TLR3, TLR7
and TLR8 have been implicated in the context of viral infec-
tion whereas TLR9 is involved in the recognition of both bac-
terial and viral DNA [33–36]. TLR3 is highly expressed in
macrophages, dendritic cells and epithelial cells [37] and in-
duces the expression of IFN-b following exposure to double
stranded (d/s) RNA. TLRs 7 and 9 are expressed in a subset
of DCs called plasmacytoid DCs or pre-DC2 cells. Exposure
of these cells to ssRNA or DNA from viral genomes results
in the secretion of large amounts of IFN-a. These receptors
also diﬀer in their signaling proﬁles.
3.1. TLR3
TLR3 functions independently of MyD88 requiring only
the adaptor TRIF to transmit signals to the nucleus whereas
TLR7, TLR8 and TLR9 all signal via MyD88. TLR3 can
activate NF-jB to some extent and this is thought to be med-
iated by the interaction of RIP1 with TRIF. As described for
TLR4, TRIF also recruits the kinases TBK1 and IKKi to
activate IRF-3. It was originally believed that TBK1 and
IKKi associate with TANK (TRAF family member-asssoci-
ated NF-jB activator), however a recent study by Sasai
et al. [22] has revealed that it is the TANK homolog,
NAP1 (NF-jB-activating kinase (NAK)-associated protein
1) that forms a functional complex with TBK1 and IKKi
rather than TANK itself.A detailed study examining the phosphorylation status of
TLR3 has been carried out by Sakar and colleagues [38,39].
These workers demonstrated that phosphorylation of TLR3
on Tyr759 facilitates the recruitment of PI3K. Mutation of this
residue to phenylalanine not only prevented TLR3/PI3K com-
plex formation but also resulted in only a partial phosphoryla-
tion of IRF3 and a failure to induce target genes.
Phosphorylation on Tyr858 was also found to be critical for full
IRF-3 activation. In a simpliﬁed scenario, phosphorylated
TLR3 recruits both TRIF and PI3K. TRIF in turn recruits
the kinase complex NAP1/IKKi /TBK1 leading to partial
IRF3 phosphorylation. At the same time, PI3K (presumably
acting through AKT) initiates a kinase cascade that results
in full IRF3 phosphorylation and transcriptional activation.
This pathway mimics the one seen with TLR2 and 4 where
PI3K mediates the transactivation of NF-jB (see Fig. 2).
3.2. TLR7, TLR8 and TLR9
Details of the molecular mechanisms governing induction of
IFNs by TLR7, TLR8 and TLR9 are beginning to emerge.
Unlike TLR3, these receptors signal in a MyD88 dependent
manner to activate IRF-3 related transcription factors. Kawai
and colleagues have recently demonstrated that MyD88 and
TRAF6 directly associate with IRF7 to induce IFN-a follow-
ing stimulation of cells with ligands for TLR7 and TLR9 [40].
Silencing of the ubiquitin-conjugating enzyme, UBC13, re-
duces the activation of IFN-a promoters indicating that the
ubiquitin ligase activity of TRAF6 is required for the activa-
tion of IRF-7. In a follow up study, Uematsu and coworkers
demonstrated that IRAK-1 also participates in the activation
of IRF-7 possibly through direct phosphorylation as suggested
by in vitro kinase assays [41]. It should be noted however that
TBK1 and IKKi have also been shown to phosphorylate IRF-
7 [42] and further studies will be required to identify the direct
eﬀectors of this transcription factor.
IRF-5 is the latest member of the IRF family found to be
activated by TLR ligands [43], however its activation is much
more restricted when compared to IRF-3 and IRF-7. Indeed
many viruses that activate IRF-3 and IRF-7 fail to activate
IRF-5. Recent studies have demonstrated that IRF-5, like
IRF-7, is activated by TLR7 and TLR8 [44] and complexes
with both MyD88 and TRAF6 [43]. Hence IRF-5 displays
characteristics comparable to IRF-7.4. Negative regulation of TLR signaling
As discussed above, activation of TLRs by pathogens of
bacterial or viral origin typically leads to the production of
pro-inﬂammatory mediators such as (IL-1), cyclooxygenase,
nitric oxide, adhesion molecules and chemokines. Excessive
production of these molecules contributes to the pathogenesis
of inﬂammatory diseases such as rheumatoid arthritis and in
the case of bacterial LPS, septic shock. It is therefore critical
that checkpoints are put in place to maintain tissue homeosta-
sis and prevent excessive damage to the host. Several molecules
have been described recently that function in this particular
capacity. For example, IRAK-M, a kinase inactive IRAK fam-
ily member, prevents the disssociation of IRAK-1 from
MyD88 and the subsequent association of IRAK-1 with the
downstream adaptor TRAF6. IRAK-M deﬁcient mice are hy-
per-responsive to LPS challenge and exhibit reduced tolerance
Fig. 2. Summary of TLR signaling pathways. A common feature of TLR signaling pathways is the recruitment of speciﬁc adaptor molecules into
receptor complexes, the initiation of kinase cascades and the induction of gene expression following the activation of transcription factors such as
NF-jB and IRF family members.
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ant of MyD88, termed MyD88s, also inhibits LPS/IL-1 in-
duced NF-jB activity by preventing the association of
IRAK-1 with IRAK-4 and the subsequent activation of
IRAK-1. At the receptor level, two proteins termed SIGGIR
and T1/ST2 (which are themselves orphan receptors) have
been shown to be involved in the negative regulation of TLR
signaling. SIGGIR-deﬁcient mice show enhanced responses
to IL-1 and TLR ligands and are more susceptible to inﬂam-
matory disorders [45] while T1/ST2 deﬁcient mice show defec-
tive induction of LPS tolerance [46].
More recently, the conjugation of ubiquitin to intracellular
signaling proteins has been described as an important mecha-
nism regulating TLR responses. As mentioned above, TRAF6
undergoes ubiquitination on activation. Jensen and Whitehead
[47] ﬁrst observed that TRAF6 is recycled via deubiquitination
following treatment of cells with IL-1. Boone et al. [48] then
went on to show that the deubiquitinating enzyme, A20, re-
turns TRAF6 to an unmodiﬁed state and in doing so termi-
nates TLR responses. Indeed A20 is induced by a variety
and TLR ligands and macrophages deﬁcient in the enzyme
show enhanced NF-jB activity following cell stimulation. In
addition, A20 knockout mice are more susceptible to endo-
toxin enduced shock when compared to wild-type mice.
Triad3A, a novel RING-type E3 ubiquitin-ligase was re-
cently shown to promote the degradation of TLR3, TLR4,
TLR5 and TLR9 but not TLR2 [49]. Depletion of Triad3A
from cells using small interfering RNAs enhanced responses
to LPS, ﬂagellin and CpG DNA and led to the increased
expression of TLR4 and TLR9. As well as ubiquitinating theTLRs, Triad3A was also found to undergo autoubiqutination
similar to TRAF6. It will be interesting to discover if a novel
E3 ubiquitin ligase exists to regulate TLR2 levels or whether
TLR2 exhibits prolonged stability when compared to other
TLRs.5. Concluding remarks
The repertoire of molecules modulating TLR signaling has
expanded greatly since the discovery that these receptors are
responsible for the recognition of microbial components. Dif-
ferences are also beginning to emerge in the signaling pathways
activated by diﬀerent TLRs. Collectively, these diﬀerences
ensure that the host response is eﬀective in eradicating a pleth-
ora of infectious agents given the limited number of receptor
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